摘要
目的:研究DC-CIK免疫治疗联合常规化疗对晚期胃癌患者血清学指标及外周血免疫功能指标的影响。方法:将2013年5月~2014年6月期间在我院接受治疗的80例晚期胃癌患者纳入研究,随机分为两组,观察组患者接受DC-CIK免疫治疗联合常规化疗,对照组患者接受常规化疗,比较两组患者的血清胃癌活力指标、信号通路分子含量以及外周血中免疫分子的表达情况。结果:(1)胃癌活力指标:观察组患者血清中血管内皮生长因子(VEGF)、缺氧诱导因子(HIF-1α)、DDK1、EXOSC、脾酪氨酸激酶(Syk)含量低于对照组(P〈0.05);(2)信号通路功能:观察组患者血清中增殖信号通路分子Ras、细胞外信号调节蛋白激酶(ERK)、c-Jun氨基末端激酶(JNK)含量低于对照组(P〈0.05),抗氧化信号通路分子Nrf2、ARE含量高于对照组(P〈0.05);(3)免疫分子:观察组患者肿瘤促进分子CD168、CD133、CD151的含量低于对照组(P〈0.05),肿瘤抑制分子CD9、CD63的含量高于对照组(P〈0.05)。结论:DC-CIK免疫治疗联合常规化疗有助于杀灭胃癌细胞,抑制增殖信号通路功能,增强抗氧化信号通路功能,调节免疫分子表达,是治疗晚期胃癌的理想方法。
Objective: To study the effect of DC-CIK immune therapy combined with conventional chemotherapy on ser um index and peripheral blood immune function of patients with advanced gastric carcinoma. Methods.. A total of 80 cases with advanced gastric cancer in our hospital from 2013 May to 2014 June were enrolled and randomly divided into two groups. Patients in observation group received DC-CIK immune therapy combined with conventional chemotherapy, control group received conventional ehemotherapy. Then gastric cancer vigor index, signal pathway molecule content and immune molecule content in peripheral brood were compared. Results: Serum VEGF, HIF-1α, DDK1, EXOSC, Syk contents of observation group were lower than those of control group. Serum proliferation signal pathway molecule Ras, ERK, JNK contents of observation group were lower than those of control group. antioxidant signal pathway molecule Nrf2 and ARE contents were higher than those of control group. Tumor promoting molecules CD168, CD133, CD151 contents of observation group were lower than those of control group; tumor suppressor molecules CD9, CD63 contents were higher than those of control group. Conclusion: DC-CIK immune therapy combined with conventional chemotherapy is helpful to kill tumor cells, inhibit proliferation pathway function, enhance antioxidant signaling pathways function and regulate immune molecule expression; it's an ideal method in treating advanced gastric cancer.
出处
《海南医学院学报》
CAS
2015年第7期981-983,987,共4页
Journal of Hainan Medical University
基金
武汉市卫生局临床医学科研项目(DC11A08)~~